文献速递妇科

综合癌症中心妇科手术中甲硝唑联合头孢唑林与单用头孢唑林预防手术部位感染的比较

Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center.
PubMed 文献 · Am J Obstet Gynecol · 2024-04-08

这项回顾性单中心队列研究纳入2017年5月至2023年6月在妇科肿瘤科手术的3343例患者,比较干预前后手术部位感染率。干预后(头孢唑林加甲硝唑)30天手术部位感染率为2.6%,低于干预前的4.7%(P=.010);多因素分析中干预后组感染比值比为0.49(95%CI 0.38-0.63)。

要点

  • 干预后组30天手术部位感染率为2.6%,低于干预前组的4.7%(P=.010)。
  • 多因素分析中,干预后组相比干预前组手术部位感染比值比为0.49(95%CI 0.38-0.63)。
  • 作者建议妇科手术、尤其全子宫切除术者可考虑头孢唑林联合甲硝唑方案。

核心结论

  • 妇科手术前在头孢唑林基础上加用甲硝唑使手术部位感染率减半,该结果在调整其他已知预测因素和不同时期实践模式差异后仍成立。
  • 作者认为提供者应考虑在妇科手术女性中采用该联合方案,尤其涉及全子宫切除术的病例。

研究设计与样本

  • 回顾性单中心队列研究,纳入2017年5月至2023年6月在妇科肿瘤科手术的患者。
  • 排除青霉素过敏者以及同时行肠切除和/或联合关节手术者。
  • 干预前组手术时间为2017年5月至2022年4月,干预后组为2022年4月至2023年6月。
  • 共3343例患者,干预前组2572例(76.9%),干预后组771例(23.1%)。
  • 主要结局为30天手术部位感染率,采用多因素logistic回归模型识别独立相关因素并调整混杂变量。

主要发现

  • 干预前组接受适当术前抗生素的比例为95.6%,高于干预后组的90.7%(P<.001)。
  • 总体手术部位感染率干预前为4.7%,干预后为2.6%(P=.010)。
  • 全子宫切除术患者手术部位感染率干预前为4.9%,干预后为2.8%(P=.036);良性病例中干预前为4.4%,干预后为2.4%(P=.159)。
  • 多因素分析中,干预后组相比干预前组手术部位感染比值比为0.49(95%CI 0.38-0.63;P<.001)。
  • 敏感性分析(n=3087)中,单用头孢唑林者手术部位感染率为4.5%,头孢唑林联合甲硝唑者为2.3%,联合组调整比值比为0.40(95%CI 0.30-0.53;P<.001)。

关键数值与推荐

  • 当前指南推荐在子宫切除术等清洁-污染手术前给予头孢唑林以降低手术部位感染率。
  • 干预后组30天手术部位感染率为2.6%,干预前组为4.7%(P=.010)。
  • 多因素分析中干预后组相比干预前组手术部位感染比值比为0.49(95%CI 0.38-0.63;P<.001)。
  • 敏感性分析中头孢唑林联合甲硝唑组相比单用头孢唑林组手术部位感染调整比值比为0.40(95%CI 0.30-0.53;P<.001)。
  • 全子宫切除术患者中干预后组相比干预前组手术部位感染调整比值比为0.63(95%CI 0.47-0.86;P=.003)。

临床怎么用

  • 作者认为提供者应考虑在妇科手术女性中采用头孢唑林联合甲硝唑方案,尤其涉及全子宫切除术的病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical site infection is one of the most common complications of gynecologic cancer surgery. Current guidelines recommend the administration of cefazolin preoperatively to reduce surgical site infection rates for patients undergoing clean-contaminated surgeries such as hysterectomy. OBJECTIVE: To evaluate the impact of a quality improvement project adding metronidazole to cefazolin for antibiotic prophylaxis on surgical site infection rate for women undergoing gynecologic surgery at a comprehensive cancer center. STUDY DESIGN: This retrospective, single-center cohort study included patients who underwent surgery in the gynecologic oncology department from May 2017 to June 2023. Patients with penicillin allergies and those undergoing concomitant bowel resections and/or joint cases were excluded. The preintervention group patients had surgery from May 2017 to April 2022, and the postintervention group patients had surgery from April 2022 to June 2023. The primary outcome was a 30-day surgical site infection rate. Sensitivity analyses were performed to compare surgical site infection rates on the basis of actual antibiotics received and for those who had a hysterectomy. Factors independently associated with surgical site infection were identified using a multivariable logistic regression model adjusting for confounding variables. RESULTS: Of 3343 patients, 2572 (76.9%) and 771 (23.1%) were in the pre-post intervention groups, respectively. Most patients (74.7%) had a hysterectomy performed. Thirty-four percent of cases were for nononcologic (benign) indications. Preintervention patients were more likely to receive appropriate preoperative antibiotics (95.6% vs 90.7%; P<.001). The overall surgical site infection rate before the intervention was 4.7% compared with 2.6% after (P=.010). The surgical site infection rate for all patients who underwent hysterectomy was 4.9% (preintervention) vs 2.8% (postintervention) (P=.036); a similar trend was seen for benign cases (4.4% vs 2.4%; P=.159). On multivariable analysis, the odds ratio for surgical site infection was 0.49 (95% confidence interval, 0.38-0.63) for the postintervention compared with the preintervention group (P<.001). In a sensitivity analysis (n=3087), the surgical site infection rate was 4.5% for those who received cefazolin alone compared with 2.3% for those who received cefazolin plus metronidazole, with significantly decreased odds of surgical site infection for the cefazolin plus metronidazole group (adjusted odds ratio, 0.40 [95% confidence interval, 0.30-0.53]; P<.001). Among only those who had a hysterectomy performed, the odds of surgical site infection were significantly reduced for those in the postintervention group (adjusted odds ratio, 0.63 [95% confidence interval, 0.47-0.86]; P=.003). CONCLUSION: The addition of metronidazole to cefazolin before gynecologic surgery decreased the surgical site infection rate by half, even after accounting for other known predictors of surgical site infection and differences in practice patterns over time. Providers should consider this combination regimen in women undergoing gynecologic surgery, especially for cases involving hysterectomy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Knisely A, Iniesta MD, Marten CA, et al. Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center. Am J Obstet Gynecol. 2024. PMID: 38599478. doi:10.1016/j.ajog.2024.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。